MultiplexDX is a pioneering biotech company focused on revolutionizing the field of personalized molecular diagnostics. The company's primary mission is to eliminate cancer misdiagnosis by developing highly accurate, quantitative, and accessible diagnostic tests. MultiplexDX operates in the healthcare and biotechnology market, serving medical professionals, hospitals, and research institutions that require precise diagnostic tools.

The company has made significant strides in the biotech industry, including the development of key components for the first Slovak IVD (In Vitro Diagnostic) certified PCR diagnostic kit for COVID-19, which was financed by the ESET Foundation. Additionally, MultiplexDX has received grants from the Slovak Ministry of Health and the EIC Accelerator, underscoring its credibility and innovative capabilities.

MultiplexDX's business model revolves around the creation and sale of advanced diagnostic products and services. These include custom oligonucleotide synthesis, coronavirus qPCR probes and primers, RNA sequencing kits, and fluorescent in situ hybridization (FISH) probes. The company generates revenue by selling these products and offering related services to its clients, which include healthcare providers and research organizations.

The company is headquartered in Bratislava and has been recognized for its excellence in the biotech field, winning the Biotech Standard of Excellence WebAward in 2018 and the Best Social Impact Startup in the CEE Region at the CESAwards.

In summary, MultiplexDX is a biotech company dedicated to improving diagnostic accuracy in healthcare, particularly in cancer diagnostics. It serves medical professionals and research institutions by providing innovative diagnostic tools and services, thereby generating revenue through product sales and service offerings.

Keywords: biotech, diagnostics, cancer, COVID-19, PCR, RNA sequencing, oligonucleotides, healthcare, innovation, personalized medicine.